TransMedics Raises 2026 Revenue Guidance Amid Shift in Regulatory Catalysts
TransMedics Group (TMDX) reported its strongest third quarter to date, achieving record revenue and case volumes. Following these results, the company raised its full-year 2026 revenue guidance to a range of $764 million to $774 million. Despite the strong financial performance, management noted a shift in the timeline for key regulatory catalysts. The ENHANCE Part B and DENOVO milestones, previously anticipated sooner, are now expected to occur in early 2027. This adjustment provides clarity on the company's long-term growth trajectory while recalibrating near-term expectations regarding product expansions.
Tickers: $TMDX
Topics: case volume earnings report revenue growth